Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving Average – What’s Next?

Aktis Oncology (NASDAQ:AKTS)’s stock price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $23.59 and traded as high as $25.22. Aktis Oncology shares last traded at $24.63, with a volume of 244,597 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on AKTS. HC Wainwright boosted their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Raymond James Financial initiated coverage on Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target for the company. JPMorgan Chase & Co. lifted their price target on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Finally, William Blair began coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.60.

Aktis Oncology Stock Down 3.2%

The stock’s 50-day simple moving average is $23.78. The firm has a market capitalization of $1.28 billion and a PE ratio of -63.18.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Monday, May 11th. The technology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The business had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $2.23 million. As a group, equities research analysts expect that Aktis Oncology will post -1.64 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.